#MAZDUTIDE - Twitter Hashtag

about 2 months ago

Mazdutide shows impressive weight loss and waist reduction in a major phase 3 trial for Chinese adults with obesity. Significant cardiometabolic benefits, but GI side effects need attention. 💊📉 https://t.co/ykjQMcKSqb #Mazdutide #Obesity @JAMANetwork

NewsMedical's tweet photo. Mazdutide shows impressive weight loss and waist reduction in a major phase 3 trial for Chinese adults with obesity. Significant cardiometabolic benefits, but GI side effects need attention. 💊📉
https://t.co/ykjQMcKSqb #Mazdutide #Obesity @JAMANetwork https://t.co/uaJo1P7Hsa

0

3

1

0

220

ALI ALKHALIFAH |:| عـلـي الخـليـفـة

@AliAl_khalifah

about 2 months ago

هل نحن أمام منافس جديد يغير قواعد اللعبة في عالم خسارة الوزن؟ 🥊🔥 نتائج مذهلة نُشرت حديثاً في مجلة JAMA لعقار مازدوتيد #Mazdutide (بجرعة 9 ملغ أسبوعياً): 📉 حقق متوسط خسارة وزن مذهل وصل إلى 17% لدى البالغين المصابين بالسمنة، مقارنة بـ 2% فقط لمن تناولوا الدواء الوهمي (Placebo). 🛑 الجانب الآخر: أغلب المشاركين أبلغوا عن أعراض جانبية في الجهاز الهضمي (مثل الغثيان والاضطرابات)، لكنها كانت "خفيفة إلى متوسطة. الدواء يعتمد على آلية ثنائية متطورة (GLP-1 + Glucagon)، ويبدو أن سباق أدوية الرشاقة يزداد شراسة🧪🧬 ما رأيكم.. هل ستتفوق هذه الأدوية تماماً على جراحات السمنة مستقبلاً؟ 👇 #ADA2026 #صحة #طب #أبحاث_علمية

AliAl_khalifah's tweet photo. هل نحن أمام منافس جديد يغير قواعد اللعبة في عالم خسارة الوزن؟ 🥊🔥

نتائج مذهلة نُشرت حديثاً في مجلة JAMA لعقار مازدوتيد #Mazdutide (بجرعة 9 ملغ أسبوعياً):
📉 حقق متوسط خسارة وزن مذهل وصل إلى 17% لدى البالغين المصابين بالسمنة، مقارنة بـ 2% فقط لمن تناولوا الدواء الوهمي (Placebo).
🛑 الجانب الآخر: أغلب المشاركين أبلغوا عن أعراض جانبية في الجهاز الهضمي (مثل الغثيان والاضطرابات)، لكنها كانت "خفيفة إلى متوسطة.
الدواء يعتمد على آلية ثنائية متطورة (GLP-1 + Glucagon)، ويبدو أن سباق أدوية الرشاقة يزداد شراسة🧪🧬

ما رأيكم.. هل ستتفوق هذه الأدوية تماماً على جراحات السمنة مستقبلاً؟ 👇
#ADA2026 #صحة #طب #أبحاث_علمية

2

13

3

5

1K

Pep pharmacy @Dr_peptide1

4 months ago

Buy pure quality Peptides for sale here #RETATRUTIDE #DERMORPHIN #GLUTATHIONE #INSULIN #BACWATER #BOTULINUMTOXIN #5AMINO1MQ #HMG #EPO #CEREBROLYSIN #CAGRILINTIDE #ARA290 #SNAP8 #MAZDUTIDE

0

1

957

Minhua Chu

@chuminhua432

11 months ago

🇨🇳 #Innovent Biologics' dual glucagon/GLP-1 receptor agonist #mazdutide, has been approved for a new indication for marketing, for glycemic control in adult patients with type 2 diabetes. Previously, the drug has been approved for long-term weight management in adult patients with obesity or overweight. https://t.co/j40byVUebs Innovent licensed mazdutide from Eli Lilly.

Minhua Chu

@chuminhua432

about 1 year ago

🇨🇳 #Innovent Biologics announced Friday that #mazdutide, a dual #glucagon/GLP-1 receptor agonist licensed from $LLY in 2019, was approved by Chinese #NMPA for chronic weight management in adults with overweight or obesity. https://t.co/BsccMiRmwo The decision was based on data from the Chinese Phase III GLORY-1 trial, which were presented #ADA2024 https://t.co/f3hfZ6Ylse At week 32, those taking the high dose saw placebo-adjusted weight loss of 13%, which increased to 14.3% at week 48. Mazdutide is under NMPA review for type 2 diabetes In DREAMS-2, the high dose of mazdutide lowered HbA1c by 1.73% from baseline at 28 weeks, versus 1.36% for Trulicity. https://t.co/83O5Pr4f7Z

chuminhua432's tweet photo. 🇨🇳 #Innovent Biologics announced Friday that #mazdutide, a dual #glucagon/GLP-1 receptor agonist licensed from $LLY in 2019, was approved by Chinese #NMPA for chronic weight management in adults with overweight or obesity. https://t.co/BsccMiRmwo

The decision was based on data from the Chinese Phase III GLORY-1 trial, which were presented #ADA2024 https://t.co/f3hfZ6Ylse At week 32, those taking the high dose saw placebo-adjusted weight loss of 13%, which increased to 14.3% at week 48.

Mazdutide is under NMPA review for type 2 diabetes
In DREAMS-2, the high dose of mazdutide lowered HbA1c by 1.73% from baseline at 28 weeks, versus 1.36% for Trulicity. https://t.co/83O5Pr4f7Z

2

9

1

0

1K

0

5

0

1K

Dr. José Luis Neyro @doctorneyro

about 1 year ago

#Glucagonreceptor #GCGR-based multi-agonist drugs are emerging as promising treatments for #obesity, with several in advanced stages of clinical development. Agents like #mazdutide, #pemvidutide, #survodutide and #retatrutide https://t.co/70ON1AXKtp

doctorneyro's tweet photo. #Glucagonreceptor #GCGR-based multi-agonist drugs are emerging as promising treatments for #obesity, with several in advanced stages of clinical development.

Agents like #mazdutide, #pemvidutide, #survodutide and #retatrutide

https://t.co/70ON1AXKtp https://t.co/fDNtAtOxhm

0

3

0

533

Minhua Chu

@chuminhua432

about 1 year ago

🇨🇳 #Innovent Biologics announced Friday that #mazdutide, a dual #glucagon/GLP-1 receptor agonist licensed from $LLY in 2019, was approved by Chinese #NMPA for chronic weight management in adults with overweight or obesity. https://t.co/BsccMiRmwo The decision was based on data from the Chinese Phase III GLORY-1 trial, which were presented #ADA2024 https://t.co/f3hfZ6Ylse At week 32, those taking the high dose saw placebo-adjusted weight loss of 13%, which increased to 14.3% at week 48. Mazdutide is under NMPA review for type 2 diabetes In DREAMS-2, the high dose of mazdutide lowered HbA1c by 1.73% from baseline at 28 weeks, versus 1.36% for Trulicity. https://t.co/83O5Pr4f7Z

2

9

1

0

1K

Scott Isaacs

@scottisaacsmd

about 1 year ago

Once weekly #mazdutide with up to 14% weight loss in a phase 3, double-blind 48-week placebo-controlled trial in China. https://t.co/GEIIrkgagR

scottisaacsmd's tweet photo. Once weekly #mazdutide with up to 14% weight loss in a phase 3, double-blind 48-week placebo-controlled trial in China.
https://t.co/GEIIrkgagR https://t.co/Zhwzf62Chq

2

92

17

24

7K

Neil Floch MD

@NeilFlochMD

about 1 year ago

Not such great results for #Mazdutide GLP-1 and glucagon agonist

Dr Alo, DO, FACC

@MohammedAlo

about 1 year ago

Mazdutide For Obesity 1️⃣ Mazdutide is a dual agonist that activates both GLP-1 and glucagon receptors. 2️⃣ In this new study, after 48 weeks, the average weight change from baseline was: •⁠ Placebo: +0.30% •⁠ 4mg: –11.00% •⁠ 6mg: –14.01% 3️⃣ Discontinuation rates were low: •⁠ ⁠4mg: 1.5% •⁠ ⁠6mg: 0.5% •⁠ ⁠Placebo: 1.0% The future of obesity treatment looks bright 💪 @NutritionMadeS3 @theproof @DrNadolsky @DrKarlNadolsky @drmatthewnagra @MichaelAlbertMd @MichaelMindrum @BevTchangMD Study Link: https://t.co/8ImHrDLFD5

MohammedAlo's tweet photo. Mazdutide For Obesity

1️⃣ Mazdutide is a dual agonist that activates both GLP-1 and glucagon receptors.

2️⃣ In this new study, after 48 weeks, the average weight change from baseline was:

•⁠ Placebo: +0.30%
•⁠ 4mg: –11.00%
•⁠ 6mg: –14.01%

3️⃣ Discontinuation rates were low:

•⁠ ⁠4mg: 1.5%
•⁠ ⁠6mg: 0.5%
•⁠ ⁠Placebo: 1.0%

The future of obesity treatment looks bright 💪

@NutritionMadeS3 @theproof @DrNadolsky @DrKarlNadolsky @drmatthewnagra @MichaelAlbertMd @MichaelMindrum @BevTchangMD

Study Link: https://t.co/8ImHrDLFD5

4

26

8

4K

0

6

1

2

1K

Minhua Chu

@chuminhua432

about 1 year ago

🇨🇳 #Innovent announces that the results of a Phase 3 clinical study of #mazdutide , a dual GCG/GLP-1 receptor agonist, in Chinese adults with overweight or obesity (GLORY-1) have been published in #NEJM https://t.co/X6JzFnnFZu; https://t.co/x3tmynpVo7 Based on the efficacy estimand, the mean percent change from baseline in body weight was −10.97%, −13.38%, and −0.24% at Week 32 and −12.05%, −14.84%, and −0.47% at Week 48 in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. A total of 76.3% of participants in the mazdutide 4 mg group and 84.0% in the mazdutide 6 mg group had a weight reduction of ≥5% at week 32, compared with 10.9% in the placebo group; 37.0% of participants in the mazdutide 4 mg group and 50.6% in the mazdutide 6 mg group had a weight reduction of ≥15% at week 48, compared with 2.1% in the placebo group.

chuminhua432's tweet photo. 🇨🇳 #Innovent announces that the results of a Phase 3 clinical study of #mazdutide , a dual GCG/GLP-1 receptor agonist, in Chinese adults with overweight or obesity (GLORY-1) have been published in #NEJM https://t.co/X6JzFnnFZu; https://t.co/x3tmynpVo7

Based on the efficacy estimand, the mean percent change from baseline in body weight was −10.97%, −13.38%, and −0.24% at Week 32 and −12.05%, −14.84%, and −0.47% at Week 48 in the mazdutide 4 mg, 6 mg, and placebo groups, respectively.

A total of 76.3% of participants in the mazdutide 4 mg group and 84.0% in the mazdutide 6 mg group had a weight reduction of ≥5% at week 32, compared with 10.9% in the placebo group; 37.0% of participants in the mazdutide 4 mg group and 50.6% in the mazdutide 6 mg group had a weight reduction of ≥15% at week 48, compared with 2.1% in the placebo group.

0

10

2

2K

Minhua Chu

@chuminhua432

over 1 year ago

🇨🇳 #Innovent $IVBXF registered a Ph3 open-label head to head study (GLORY-3) in #China. The trial aims to compare the efficacy and safety of #Mazdutide versus Semaglutide in overweight or obese patients with MAFLD. /1

1

5

0

598

EjeCentral

@EjeCentral

over 2 years ago

Un nuevo medicamento está causando furor luego de que se conociera que puede hacer bajar a quien lo consume casi 20 kilos por año: se trata del #Mazdutide - https://t.co/Ngz9W3shXM

0

1

0

375

On The Pen™

@ManOnThePen

almost 3 years ago

@EliLillyandCo has new blockbuster #obesitymedicine and it isn’t #mounjaro #tirzepatide or #retatrutide! This one is called #mazdutide

0

4

0

1

733

Evaluate Japan @EvaluateJP

about 4 years ago

#Lilly はどちらを選ぶべきか？ GIP/GLP-1/グルカゴン受容体 #トリプルアゴニスト #LY3437943 は、血糖値と体重減少を示し、GLP-1/グルカゴン受容体の #デュアルアゴニスト #Mazdutide も、ADAで強力なデータを示した。 https://t.co/fq0jNpgpJE #Evaluate

0

4

3

0

Top Tweets for #MAZDUTIDE

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users